ESHRE: Low evidence of fertility drug and cancer link

Share this content:
ESHRE: Reassuring Findings on Fertility Drug-Cancer Link
ESHRE: Reassuring Findings on Fertility Drug-Cancer Link

(HealthDay News) -- Use of fertility drugs doesn't appear to increase a woman's long-term risk of breast, ovarian, and uterine cancers, new research indicates. The findings were presented this week at the annual meeting of the European Society of Human Reproduction and Embryology in Munich.

Nearly 10,000 women who underwent infertility treatment in the United States between 1965 and 1988 were followed for 30 years for the study. During the follow-up, 749 cases of breast cancer, 119 cases of uterine cancer, and 85 cases of ovarian cancer were diagnosed among the women.

The researchers found "little evidence" that the use of conventional fertility drugs increased the long-term risk of breast, uterine, or ovarian cancers. However, extended use of clomiphene citrate was associated with a higher risk of breast cancer among women who used the fertility drug for 12 cycles or more, the research team said. In general, the use of gonadotrophins was not associated with increased cancer risk, except in women who remained childless after undergoing fertility treatment, the investigators found.

The findings are "generally reassuring," said study coauthor Humberto Scoccia, M.D., of the University of Illinois at Chicago. Still, he urged that women who use fertility drugs be closely monitored as they age.

Full Article
More Information

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs